Theranib Inc.

At Theranib Inc., we are dedicated to revolutioning cancer treatment by addressing the most pressing challenges in oncology: chemotherapy resistance and metastasis. Through our groundbreaking research and development of ALDH1A3-targeted therapies, we aim to deliver life-changing solutions for patients worldwide. Founded by leading scientists from Dalhousie University in Nova Scotia, Canada, and the University of Pisa, Italy, Theranib combines world-class expertise in molecular cancer biology and medicinal chemistry. Our proprietary compound, CLM296, represents a first-in-class therapeutic innovation designed to enhance the effectiveness of cancer treatments and improve patient outcomes. Supported by key funding sources, including the Canadian Institutes of Health Research and Invest Nova Scotia, we are advancing our mission to set a new standard in precision medicine. With a strong commitment to innovation and collaboration, Theranib is paving the way for the future of cancer care.